• HOME
• Makeup Skin Care
• Understanding RNA (CAS 63231-63-0) and Its Market Price

I. Introduction to RNA (CAS 63231-63-0)

Ribonucleic Acid (RNA) is a fundamental biomolecule essential for the coding, decoding, regulation, and expression of genes. Unlike its more famous counterpart, DNA, RNA is typically single-stranded and contains the sugar ribose. Its structure is composed of a long chain of nucleotides, each consisting of a nitrogenous base (adenine, guanine, cytosine, or uracil), a ribose sugar, and a phosphate group. Functionally, RNA is incredibly versatile, serving as a messenger (mRNA) carrying genetic instructions from DNA for protein synthesis, as a structural and catalytic component in ribosomes (rRNA), and as a transfer molecule (tRNA) that brings amino acids to the ribosome. Beyond these classical roles, various non-coding RNAs, such as microRNAs and siRNAs, play critical roles in regulating gene expression and cellular defense.

The CAS Registry Number 63231-63-0 specifically identifies a type of RNA, often referring to research-grade or synthetic RNA oligonucleotides. This unique identifier is crucial in scientific and commercial contexts to eliminate ambiguity. When a researcher or procurement specialist searches for "RNA CAS NO.63231-63-0," they are pinpointing a specific, well-defined chemical entity, not the broad class of molecules. This specificity is vital for reproducibility in experiments, regulatory compliance, and accurate pricing in the biochemical market. It ensures that the product in question has a documented chemical structure and purity profile.

The applications of RNA, particularly those specified by CAS 63231-63-0, are vast and growing. In basic research, synthetic RNA oligonucleotides are indispensable tools for studying gene function, RNA interference (RNAi), and CRISPR-Cas9 gene editing systems. In the pharmaceutical industry, RNA-based therapeutics, such as mRNA vaccines (exemplified by COVID-19 vaccines) and siRNA drugs, represent a revolutionary class of medicines. Diagnostic applications are equally significant, with RNA probes used in techniques like RT-PCR and next-generation sequencing for detecting pathogens and profiling gene expression. The purity and specificity of the RNA, guaranteed by its CAS registration, are non-negotiable in these high-stakes applications. It is worth noting that the production of high-grade RNA often relies on high-purity precursors. For instance, the amino acid L-Glycine 56-40-6 is a critical component in many cell culture media and buffer systems used in the enzymatic synthesis or in vitro transcription of RNA, highlighting the interconnectedness of biochemical supply chains.

II. Factors Influencing RNA Pricing

The cost of RNA, especially research-grade material under CAS 63231-63-0, is not a single figure but a spectrum determined by a confluence of technical and commercial factors. Understanding these is key to making informed purchasing decisions.

Purity and Grade: This is the primary cost driver. RNA purity is typically measured by HPLC (High-Performance Liquid Chromatography). Research-grade (e.g., >95% pure) is suitable for many applications, but therapeutic-grade or GMP (Good Manufacturing Practice)-grade RNA, requiring purity levels of >98% or even >99.9% with stringent endotoxin and bioburden controls, commands a premium price. The cost of rigorous purification and quality control is directly reflected in the final price.

Synthesis Method: There are two main pathways: chemical synthesis and enzymatic synthesis. Chemical synthesis (solid-phase phosphoramidite chemistry) is ideal for producing short oligonucleotides (up to ~100 nucleotides) with precise sequences and modifications. It offers great flexibility but can be expensive for long sequences due to decreasing yield per cycle. Enzymatic synthesis (in vitro transcription) is more cost-effective for producing long RNA molecules (hundreds to thousands of nucleotides) and is the standard for mRNA production. The choice of method, along with the associated reagents and equipment costs, significantly impacts the price.

Quantity and Volume: As with most chemicals, bulk purchasing offers substantial discounts. A milligram-scale order for early-stage research will have a much higher per-milligram cost compared to a gram or kilogram-scale order for preclinical or clinical development. Suppliers often have tiered pricing models that incentivize larger volume commitments.

Modifications and Labeling: Native RNA is susceptible to degradation by nucleases. Modified RNA (e.g., with 2'-O-methyl, 2'-fluoro, or phosphorothioate backbones) offers enhanced stability and is essential for therapeutic applications. Fluorescent or biotin labels are used for detection and purification. Each modification adds complexity to the synthesis and purification process, thereby increasing the cost. A custom-synthesized, heavily modified siRNA will be orders of magnitude more expensive than an unmodified RNA oligo of the same length.

Supplier Reputation and Certification: The source of the RNA profoundly affects its price and reliability. Established global suppliers like Sigma-Aldrich (MilliporeSigma), Thermo Fisher Scientific, and Dharmacon (Horizon Discovery) invest heavily in quality assurance, possess relevant certifications (ISO, GMP), and provide comprehensive documentation. Their prices are generally higher than those of lesser-known or regional distributors, but they offer guaranteed sequence accuracy, purity, and batch-to-batch consistency, which are critical for reproducible science. The reputation of a supplier is a key component of the E-E-A-T framework, providing the "Authority" and "Trustworthiness" that researchers and companies depend on.

III. Market Analysis and Price Range of RNA (CAS 63231-63-0)

The global market for research and therapeutic RNA is experiencing robust growth, driven by the success of mRNA vaccines and the expanding pipeline of RNA-based drugs and diagnostics. According to market analyses relevant to the Asia-Pacific region, including Hong Kong's biotech sector, the demand for high-quality synthetic RNA is projected to grow at a compound annual growth rate (CAGR) of over 12% in the coming years. This surge is fueled by increased R&D investment in gene therapy, personalized medicine, and infectious disease research.

Price comparisons for a standard, unmodified 20-mer RNA oligonucleotide (CAS 63231-63-0) at a research scale (25 nmole scale, desalted) from major suppliers reveal a competitive landscape. The following table provides a snapshot (prices are indicative and in USD, based on recent publicly available catalogs; exact prices vary by sequence and region):

Several factors contribute to price fluctuations in this market. Supply chain disruptions, as witnessed during the pandemic, can delay the availability of key raw materials like protected nucleoside phosphoramidites (the building blocks for chemical synthesis) and enzymes for in vitro transcription, leading to temporary price hikes. The cost of raw materials themselves is volatile; for example, fluctuations in the price of Zinc Lactate CAS 6155-68-6, while not a direct RNA component, can be indicative of broader trends in fine chemical and pharmaceutical ingredient markets. Zinc lactate is used in various nutritional and pharmaceutical formulations, and its market dynamics can reflect overall production and logistic costs that indirectly affect the biochemical sector. Furthermore, geopolitical tensions and trade policies can impact the cost and availability of these specialized chemicals in regions like Hong Kong, which relies heavily on imports.

IV. Where to Buy RNA (CAS 63231-63-0) and Considerations

Procuring RNA is a decision that balances cost, quality, and application needs. For most research and development purposes, sourcing from reputable global suppliers or their authorized distributors is the recommended starting point. In Hong Kong, major international suppliers have local offices or exclusive distributors that cater to the city's vibrant academic and biotech community, such as the Hong Kong Science Park and university research centers. These local channels can provide valuable logistical support and regulatory guidance.

The Certificate of Analysis (CoA) is a non-negotiable document when purchasing RNA. A proper CoA from a reputable supplier will detail the specific CAS number (63231-63-0), the exact sequence (if applicable), the method of analysis (e.g., HPLC, MS), the measured purity, the concentration, the endotoxin level, and the appearance. It is the definitive proof of the product's identity and quality. Never accept an RNA shipment without a valid CoA, as using an uncharacterized reagent can compromise months of research.

For specialized needs, custom synthesis services are invaluable. Consider custom synthesis when you require: 1) RNA sequences not available in standard catalogs; 2) Specific and extensive chemical modifications (e.g., for therapeutic development); 3) Large-scale quantities for preclinical or clinical trials; or 4) Complex RNA structures like self-amplifying RNA or circular RNA. Many suppliers, from large corporations to niche CROs (Contract Research Organizations), offer these services. The process involves direct consultation with their scientific teams to design the optimal synthesis strategy. While more expensive and time-consuming than buying off-the-shelf, it is the only route for advanced applications. The expertise required for such custom work also underscores the importance of the "Experience" and "Expertise" pillars of E-E-A-T in selecting a synthesis partner.

V. Future Outlook and Synthesis

In summary, the pricing of RNA (CAS 63231-63-0) is a multifaceted equation shaped by purity requirements, synthesis complexity, purchase volume, the need for modifications, and the credibility of the supplier. The market is dynamic, with prices reflecting both the cutting-edge nature of the technology and the practical realities of global supply chains. As the field of RNA biology and therapeutics continues to expand at a rapid pace, the demand for high-quality RNA is expected to remain strong.

Looking ahead, several trends will likely influence the RNA market and its pricing. Technological advancements in synthesis and purification, such as continuous flow chemistry and improved chromatography techniques, may help reduce production costs over time, potentially making RNA more accessible. However, the increasing regulatory scrutiny for therapeutic-grade RNA will maintain high standards and associated costs for GMP production. The geographic landscape may also shift, with growing manufacturing capacity in Asia potentially creating more competitive pricing for bulk orders. For researchers and companies in Hong Kong and similar hubs, staying informed about these trends, building relationships with reliable suppliers, and meticulously planning procurement based on specific project needs will be essential to navigate this exciting and evolving market successfully. The integration of various biochemicals, from the foundational L-Glycine 56-40-6 in production media to stabilizing agents like Zinc Lactate CAS 6155-68-6 in final formulations, will continue to play a subtle but important role in the overall ecosystem and cost structure of RNA-based products.